                         SEQUENCE LISTING

<110>  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE en CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) 
       INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
       UNIVERSITE COTE D'AZUR
 
<120>  New anti-VEGFC antibodies and uses thereof

<130>  B379193PCTD75798

<160>  12    

<170>  PatentIn version 3.5

<210>  1
<211>  115
<212>  PRT
<213>  artificial

<220>
<223>  mature peptide of the amino acid sequence of the human VEGFC

<400>  1

Ala His Tyr Asn Thr Glu Ile Leu Lys Ser Ile Asp Asn Glu Trp Arg 
1               5                   10                  15      


Lys Thr Gln Cys Met Pro Arg Glu Val Cys Ile Asp Val Gly Lys Glu 
            20                  25                  30          


Phe Val Ala Thr Asn Thr Phe Phe Lys Pro Pro Cys Val Ser Val Tyr 
        35                  40                  45              


Arg Cys Gly Gly Cys Cys Asn Ser Glu Gly Leu Gln Cys Met Asn Thr 
    50                  55                  60                  


Ser Thr Ser Tyr Leu Ser Lys Thr Leu Phe Glu Ile Thr Val Pro Leu 
65                  70                  75                  80  


Ser Gln Gly Pro Lys Pro Val Thr Ile Ser Phe Ala Asn His Thr Ser 
                85                  90                  95      


Cys Arg Cys Met Ser Lys Leu Asp Val Tyr Arg Gln Val His Ser Ile 
            100                 105                 110         


Ile Arg Arg 
        115 


<210>  2
<211>  358
<212>  DNA
<213>  artificial

<220>
<223>  nucleic sequence of the variable region heavy chain of the 1E9 
       antibodies

<400>  2
ccaggcccaa ctgcggcagc ctggggctga actggtgaag cctggggctt cagtgaagct       60

gtcctgcaag gcttctggct acaccttcat cagctactgg atgcactggg tgaaacagag      120

gcctggacaa ggccttgagt ggattggaga gattaatcct agcaacggtc gtactaacta      180

caatgagaag ttcaagagca aggccacact gactgtagac agatcctcca gcacagccta      240

catgcaactc agcagcctga catctgagga ctctgcggtc tattactgtg caagcacctc      300

tctcttttac tatgctatga attactgggg tcaaggaacc tcagtcaccg tctcctca        358


<210>  3
<211>  336
<212>  DNA
<213>  artificial

<220>
<223>  nucleic sequence of the variable region light chain  of the 1E9 
       antibodies

<400>  3
gatgttgtga tgacccaaac tccactctcc ctgactgtca gtcttggaga tcaagcctcc       60

atctcttgca gatctagtca gagccttgta cacagtaatg gaaacaccta tttacattgg      120

tacctgcaga agccaggcca gtctccgaag ctcctgatct acaaagtttt caaccgattg      180

tctggggtcc cagacaggtt cagtggcagt ggatcaggga cagatttcac actcaagatc      240

agtagagtgg aggctgagga tctgggagtt tatttctgct ctcaaaatac gcatgttccg      300

tggacgttcg gtggaggcac caagttggaa atcaaa                                336


<210>  4
<211>  119
<212>  PRT
<213>  artificial

<220>
<223>  amino acid sequence of the heavy chain variable region (VH)  of 
       the 1E9 antibodies

<400>  4

Gln Ala Gln Leu Arg Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Ser Tyr 
            20                  25                  30          


Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Glu Ile Asn Pro Ser Asn Gly Arg Thr Asn Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Ser Lys Ala Thr Leu Thr Val Asp Arg Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ser Thr Ser Leu Phe Tyr Tyr Ala Met Asn Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Ser Val Thr Val Ser Ser 
        115                 


<210>  5
<211>  112
<212>  PRT
<213>  artificial

<220>
<223>  amino acid sequence of the light chain variable region (VL)  of 
       the 1E9 antibodies

<400>  5

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Thr Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Leu Leu Ile Tyr Lys Val Phe Asn Arg Leu Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Asn 
                85                  90                  95      


Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  6
<211>  10
<212>  PRT
<213>  artificial

<220>
<223>  highly variable region CDR-H1 of the heavy chain of the 1E9 
       antibodies

<400>  6

Gly Tyr Thr Phe Ile Ser Tyr Trp Met His 
1               5                   10  


<210>  7
<211>  18
<212>  PRT
<213>  artificial

<220>
<223>  highly variable region CDR-H2 of the heavy chain of the 1E9 
       antibodies

<400>  7

Gly Glu Ile Asn Pro Ser Asn Gly Arg Thr Asn Tyr Asn Glu Lys Phe 
1               5                   10                  15      


Lys Ser 
        


<210>  8
<211>  12
<212>  PRT
<213>  artificial

<220>
<223>  highly variable region CDR-H3 of the heavy chain of the 1E9 
       antibodies

<400>  8

Ala Ser Thr Ser Leu Phe Tyr Tyr Ala Met Asn Tyr 
1               5                   10          


<210>  9
<211>  16
<212>  PRT
<213>  artificial

<220>
<223>  highly variable region CDR-L1 of the light chain of the 1E9 
       antibodies

<400>  9

Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu His 
1               5                   10                  15      


<210>  10
<211>  7
<212>  PRT
<213>  artificial

<220>
<223>  highly variable region CDR-L2 of the light chain of the 1E9 
       antibodies

<400>  10

Lys Val Phe Asn Arg Leu Ser 
1               5               


<210>  11
<211>  9
<212>  PRT
<213>  artificial

<220>
<223>  highly variable region CDR-L3 of the light chain of the 1E9 
       antibodies

<400>  11

Ser Gln Asn Thr His Val Pro Trp Thr 
1               5                   


<210>  12
<211>  419
<212>  PRT
<213>  homo sapiens

<220>
<223>  amino-acid sequence of the human VEGFC

<400>  12

Met His Leu Leu Gly Phe Phe Ser Val Ala Cys Ser Leu Leu Ala Ala 
1               5                   10                  15      


Ala Leu Leu Pro Gly Pro Arg Glu Ala Pro Ala Ala Ala Ala Ala Phe 
            20                  25                  30          


Glu Ser Gly Leu Asp Leu Ser Asp Ala Glu Pro Asp Ala Gly Glu Ala 
        35                  40                  45              


Thr Ala Tyr Ala Ser Lys Asp Leu Glu Glu Gln Leu Arg Ser Val Ser 
    50                  55                  60                  


Ser Val Asp Glu Leu Met Thr Val Leu Tyr Pro Glu Tyr Trp Lys Met 
65                  70                  75                  80  


Tyr Lys Cys Gln Leu Arg Lys Gly Gly Trp Gln His Asn Arg Glu Gln 
                85                  90                  95      


Ala Asn Leu Asn Ser Arg Thr Glu Glu Thr Ile Lys Phe Ala Ala Ala 
            100                 105                 110         


His Tyr Asn Thr Glu Ile Leu Lys Ser Ile Asp Asn Glu Trp Arg Lys 
        115                 120                 125             


Thr Gln Cys Met Pro Arg Glu Val Cys Ile Asp Val Gly Lys Glu Phe 
    130                 135                 140                 


Val Ala Thr Asn Thr Phe Phe Lys Pro Pro Cys Val Ser Val Tyr Arg 
145                 150                 155                 160 


Cys Gly Gly Cys Cys Asn Ser Glu Gly Leu Gln Cys Met Asn Thr Ser 
                165                 170                 175     


Thr Ser Tyr Leu Ser Lys Thr Leu Phe Glu Ile Thr Val Pro Leu Ser 
            180                 185                 190         


Gln Gly Pro Lys Pro Val Thr Ile Ser Phe Ala Asn His Thr Ser Cys 
        195                 200                 205             


Arg Cys Met Ser Lys Leu Asp Val Tyr Arg Gln Val His Ser Ile Ile 
    210                 215                 220                 


Arg Arg Ser Leu Pro Ala Thr Leu Pro Gln Cys Gln Ala Ala Asn Lys 
225                 230                 235                 240 


Thr Cys Pro Thr Asn Tyr Met Trp Asn Asn His Ile Cys Arg Cys Leu 
                245                 250                 255     


Ala Gln Glu Asp Phe Met Phe Ser Ser Asp Ala Gly Asp Asp Ser Thr 
            260                 265                 270         


Asp Gly Phe His Asp Ile Cys Gly Pro Asn Lys Glu Leu Asp Glu Glu 
        275                 280                 285             


Thr Cys Gln Cys Val Cys Arg Ala Gly Leu Arg Pro Ala Ser Cys Gly 
    290                 295                 300                 


Pro His Lys Glu Leu Asp Arg Asn Ser Cys Gln Cys Val Cys Lys Asn 
305                 310                 315                 320 


Lys Leu Phe Pro Ser Gln Cys Gly Ala Asn Arg Glu Phe Asp Glu Asn 
                325                 330                 335     


Thr Cys Gln Cys Val Cys Lys Arg Thr Cys Pro Arg Asn Gln Pro Leu 
            340                 345                 350         


Asn Pro Gly Lys Cys Ala Cys Glu Cys Thr Glu Ser Pro Gln Lys Cys 
        355                 360                 365             


Leu Leu Lys Gly Lys Lys Phe His His Gln Thr Cys Ser Cys Tyr Arg 
    370                 375                 380                 


Arg Pro Cys Thr Asn Arg Gln Lys Ala Cys Glu Pro Gly Phe Ser Tyr 
385                 390                 395                 400 


Ser Glu Glu Val Cys Arg Cys Val Pro Ser Tyr Trp Lys Arg Pro Gln 
                405                 410                 415     


Met Ser Leu 
            


